Eli Lilly and (NYSE:LLY) Issues Quarterly Earnings Results

Eli Lilly and (NYSE:LLYGet Rating) posted its quarterly earnings results on Thursday. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61), Briefing.com reports. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.10%. The firm had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. During the same quarter in the previous year, the firm posted $1.87 EPS. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. Eli Lilly and updated its FY 2022 guidance to $7.90-$8.05 EPS.

Eli Lilly and Stock Performance

Shares of LLY stock traded down $4.47 on Friday, hitting $301.32. The company’s stock had a trading volume of 2,814,275 shares, compared to its average volume of 2,491,261. The company has a market capitalization of $286.30 billion, a PE ratio of 48.06, a PEG ratio of 2.26 and a beta of 0.35. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. Eli Lilly and has a fifty-two week low of $220.20 and a fifty-two week high of $335.33. The stock’s 50 day moving average is $316.10 and its 200-day moving average is $289.01.

Eli Lilly and Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be given a $0.98 dividend. This represents a $3.92 annualized dividend and a dividend yield of 1.30%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and’s payout ratio is presently 62.52%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Wells Fargo & Company upped their target price on Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. UBS Group increased their price target on Eli Lilly and to $335.00 and gave the company an “outperform” rating in a report on Wednesday, July 27th. StockNews.com lowered Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research report on Friday. The Goldman Sachs Group raised their price target on Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Finally, Morgan Stanley lifted their target price on Eli Lilly and from $369.00 to $395.00 and gave the stock an “overweight” rating in a research report on Friday, July 8th. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and presently has a consensus rating of “Moderate Buy” and a consensus price target of $316.06.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The shares were sold at an average price of $302.00, for a total value of $211,400.00. Following the sale, the insider now directly owns 105,472,666 shares in the company, valued at approximately $31,852,745,132. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the completion of the sale, the chief accounting officer now owns 6,274 shares in the company, valued at approximately $1,966,522.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 700 shares of Eli Lilly and stock in a transaction on Wednesday, May 18th. The shares were sold at an average price of $302.00, for a total transaction of $211,400.00. Following the completion of the sale, the insider now owns 105,472,666 shares of the company’s stock, valued at approximately $31,852,745,132. The disclosure for this sale can be found here. Insiders have sold 1,195,396 shares of company stock worth $380,134,601 over the last ninety days. Corporate insiders own 0.12% of the company’s stock.

Institutional Trading of Eli Lilly and

Hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its stake in Eli Lilly and by 2.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,869,274 shares of the company’s stock valued at $1,108,044,000 after acquiring an additional 83,299 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in shares of Eli Lilly and by 54.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,311,713 shares of the company’s stock worth $948,375,000 after purchasing an additional 1,172,504 shares in the last quarter. Capital Group Private Client Services Inc. boosted its stake in Eli Lilly and by 1.4% in the first quarter. Capital Group Private Client Services Inc. now owns 450,411 shares of the company’s stock worth $128,984,000 after buying an additional 6,327 shares in the last quarter. Sculptor Capital LP boosted its stake in Eli Lilly and by 61.1% in the first quarter. Sculptor Capital LP now owns 144,343 shares of the company’s stock worth $41,336,000 after buying an additional 54,722 shares in the last quarter. Finally, Wealthfront Advisers LLC boosted its stake in Eli Lilly and by 21.6% in the first quarter. Wealthfront Advisers LLC now owns 83,315 shares of the company’s stock worth $23,859,000 after buying an additional 14,806 shares in the last quarter. Institutional investors and hedge funds own 82.75% of the company’s stock.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Earnings History for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.